Antabio

Antabio is a clinical-stage biopharmaceutical company developing antibacterial treatments for life-threatening hospital infections caused by drug-resistant Gram-negative bacteria. Its lead program, Meropenem-Pilabactam, is a next-generation inhibitor combination designed to treat multi-drug resistant infections in hospital wards and intensive care units. The company also develops Pseudomonas Elastase inhibitors for chronic respiratory diseases and maintains a discovery platform for novel mechanism-of-action antibiotics.